



April 2, 2024

Company Name: SAWAI GROUP HOLDINGS Co., Ltd.

Representative: Mitsuo Sawai

Representative Director, Chairman & President, GCEO & GCOO
(Securities code: 4887, Prime Market, Tokyo Stock Exchange)

Contact: Corporate Communications

General Manager, Yasushi Kora

**Notice of Completion of Transfer (Sale of Shares / Equity Interests) of
Sawai's U.S. Subsidiary / Sub-subsidiaries**

Osaka, Japan – April 2, 2024 – As announced in the press release dated January 17, 2024, “Notice of Transfer (Sale of Shares/Equity Interests) of Sawai's U.S. Subsidiary / Sub-subsidiary,” Sawai Group Holdings Co., Ltd. (Sawai Group; Head office: Osaka, Japan; President: Mitsuo Sawai) announces that, today, Sawai Group has completed the transfer of all shares of Sawai America Holdings Inc. (SAH), a holding company of its U.S. business, as well as its interests in Sawai America LLC (SAL) and in Upsher-Smith Laboratories, LLC (Upsher-Smith), both of which are subsidiaries of SAH, to Bora Pharmaceutical Holdings, Inc. (Bora). At the same time, today, Sumitomo Corporation of Americas (SCOA), a co-investor in SAL, has also completed the transfer of its interests to Bora.

Following the completion of the transfer of these shares/interests, SAH and its subsidiaries, SAL and Upsher-Smith, have been excluded from the scope of consolidation of Sawai Group.

1. Dates

1.	Board of Directors Resolution Date	January 16, 2024
2.	Date of Agreement Execution	January 16, 2024
3.	Date of Share Transfer Execution	April 1, 2024 (U.S. Time)

2. Impact on Consolidated Profit and Loss Due to the Transfer

The impact on the profit and loss due to the transfer of these shares/interests is currently under review, and we will promptly announce the information as the details become available.